Sudarshan Pharma Industries logo

Sudarshan Pharma Industries financials: balance sheet, profit and loss, cash flow

NSE: SUDARSHANBSE: 543828Chemicals & PetrochemicalsSmall Cap

Sudarshan Pharma Industries Limited · Face value ₹1 · Listed Mar 2023
Last close ₹34.66up ₹2.67 (8.35%)BSE ₹34.88

Share price at the NSE close on 27 Oct 2026. Previous close ₹31.99.

27 Oct: open ₹33.82, high ₹35.00, low ₹32.10

52-week range of BSE trades to 27 Oct 2026
₹18.50Low, 29 Jan 2026₹42.79High, 21 Jul 2026
Market cap
₹882 Cr1,697th largest listed
P/E
35.11
P/B
Shares changed
Dividend yield
Nonein the last 12 months
ROE
17.5%
ROCE
11.8%
Debt to equity
1.81
Volume, NSE
87,43961.7% delivered

Sudarshan Pharma Industries' financial statements for the 4 years to Mar 2026, consolidated: the company and its subsidiaries together, with the twelve months to Jun 2026 after them.

4 years at a glance

₹ crore, years to March.Sudarshan Pharma Industries annual reports

Revenue, net profit and borrowings, ₹ crore

  • Revenue
  • Net profit
  • Borrowings
4617.034Mar 2346411105Mar 2450516171Mar 2570323283Mar 26
Peak revenue ₹703 Cr, year to Mar 2026; lowest ₹461 Cr, year to Mar 2023

Operating and net margin, per cent

  • Operating margin
  • Net margin
7.3%1.5%3.2%4.9%7.3%1.5%2.5%3.1%3.3%Mar 23Mar 24Mar 25Mar 26

Results for the year to Mar 2026

Consolidated: the company and its subsidiaries together. ₹ crore.

From revenue to net profit

  1. Revenue703
  2. Materials and goods−619
  3. Employee costs−7.4
  4. Other expenses−25
  5. Operating profit51
  6. Depreciation−3.8
  7. Other income+8.7
  8. One-off items0.0
  9. Finance costs−26
  10. Profit before tax31
  11. Tax−7.2
  12. Net profit23

What the company owns

  • Receivables₹233 Cr
  • Inventory₹219 Cr
  • Plant, investments and other assets₹189 Cr
  • Cash and bank₹1 Cr

What pays for it: net worth and liabilities

  • Borrowings₹283 Cr
  • Owed to suppliers₹188 Cr
  • Net worth₹156 Cr
  • Other liabilities₹14 Cr

Profit and loss

Consolidated, ₹ crore, years to March. The last column is the twelve months to Jun 2026, the latest four quarters added.Sudarshan Pharma Industries quarterly results

₹ croreMar 2023Mar 2024Mar 2025Mar 2026Jun 2026Twelve months
Revenue from operations461464505703732
447441–652676
Materials and goods bought431422440619640
Employee costs34–78
Other expenses1315–2528
Operating profit before depreciation1523–5156
Operating margin3.2%4.9%–7.3%7.7%
Materials, % of revenue93.4%91.1%–88.1%87.4%
Employee costs, % of revenue0.6%0.8%–1.1%1.1%
Other expenses, % of revenue2.8%3.2%–3.5%3.9%
Depreciation and amortisation11244
Operating profit after depreciation1422–4852
Other income13399
Finance costs59162628
Profit before one-off items and tax915243133
One-off items–––00
Profit before tax915223133
24678
711162325
Other comprehensive income–––00
Total comprehensive income–––2325
Net margin1.5%2.5%3.1%3.3%3.4%
Belonging to the company's shareholders is left blank for the year to Mar 2023: the filing's earnings per share does not match the profit it states, and cannot be multiplied back into the owners' profit because the share count in the filing and in the shareholding filing differ by more than 2%. Operating expenses, operating profit before depreciation and operating profit after depreciation are left blank for the year to Mar 2025: revenue, other income and exceptional items less the total expenses stated do not come to the profit before tax the same statement states, so the operating expenses cannot be told apart from the rest.

Balance sheet

Consolidated, ₹ crore, at 31 March.

₹ croreMar 2023Mar 2024Mar 2025Mar 2026
101112131156
101112131155
Share capital2424–24
Reserves7788–131
Belonging to outside owners of subsidiaries0001
34105171283
118161260456
13111129
Total assets232283402642
344268151
199242335490
Net debt22103169282
Borrowings are counted again inside the liabilities due within a year and after a year.

Cash flow

Consolidated, ₹ crore, years to March.

₹ croreMar 2023Mar 2024Mar 2025Mar 2026
−24−73−26−2
−22−71−234
−38−96−65−51
Receivables−8−41−38−77
Inventories−28−10−55−76
Payables18−353597
Other working capital−20−9−84
Tax paid−2−2−3−6
Capital spending142169
Free cash flow−39−75−27−71
−265−20−78
62564781
Dividends paid0100
Shares bought back–––0
Shares issued64000
Net change in cash11−1201
Capital spending is part of cash from investing, and dividends paid, shares bought back and shares issued are part of cash from financing. Each is shown as an amount on a line of its own, and the section's other items are in its total only.

Per share

Consolidated, ₹ per share, years to March.Sudarshan Pharma Industries dividend history

₹ per shareMar 2023Mar 2024Mar 2025Mar 2026
₹0.55₹0.48₹0.66₹0.97
As stated that year₹5.48₹4.76₹0.66₹0.97
₹0.55₹0.48₹0.66₹0.97
₹0.03–––
₹4.20₹4.64₹5.46₹6.44
Shareholder yield−47.8%0.4%0.0%0.0%
Market cap at the year end (₹ crore)134178735583
Every year is restated for later splits and bonuses, so they do not break the line. The figure the company stated that year is under each line it differs from.

Ratios

Consolidated, years to March.Sudarshan Pharma Industries PE ratio and valuation

RatioMar 2023Mar 2024Mar 2025Mar 2026
Revenue growth–0.5%9.0%39.2%
Operating profit growth–55.3%––
Net profit growth–62.8%38.7%47.1%
Earnings per share growth–−13.1%38.7%47.0%
–10.8%13.1%16.3%
––2.3 pts3.2 pts
From the net margin––2.9 pts0.7 pts
From asset turnover––−2.5 pts−1.2 pts
From borrowing––1.8 pts3.7 pts
Return on capital employed10.2%10.0%–10.8%
Cash conversion−347.5%−639.5%−164.3%−9.8%
Interest cover2.62.4–1.8
Debt to equity0.340.941.301.81
Receivable days6496116121
Inventory days6374117129
Payable days––76111
Cash conversion cycle, days––156139
Working capital days71137169150
Asset turnover1.981.801.471.35
Assets per rupee of net worth2.302.422.823.64
Sales per rupee of plant23.1816.9325.199.08
Capital spending to depreciation15.791.540.2618.24
Plant being built, % of plant in use–––4.4%

Growth and returns over 3, 5 and 10 years

Consolidated: the company and its subsidiaries together. Each window ends with the year to Mar 2026.

Return on assets, latest year
4.5%
Cash from operations against operating profit
−4.5%
Measure5 years3 years
Revenue growth, yearly rate–15.1%
Return on equity, average–13.4%
Return on capital employed, average–10.4%
Operating margin, average–6.1%
Net margin, average2.6%3.0%
Asset turnover, average1.651.54
Cash conversion cycle, days, average–148
Interest cover, average–2.1
Debt to equity, average1.101.35

Where the cash came from and went

Consolidated: the company and its subsidiaries together. ₹ crore, added up over each window, which ends with the year to Mar 2026.

₹ crore3 yearsLatest year
Cash from operations−102−2
Cash from investing−93−78
Cash from financing18481
Capital spending7269
Dividends paid10
Shares bought back–0
Shares issued for cash00
Borrowings raised239105
Borrowings repaid20

Accounting checks

Consolidated, years to March. Published tests of whether reported profit is backed by cash and the balance sheet.

CheckMar 2023Mar 2024Mar 2025Mar 2026
Altman Z-scorePublished threshold 1.81–––2.46
Profit not backed by cash, % of assetsPublished threshold 10 per cent of average total assets–––19.80
Receivables growth less revenue growthOur threshold 0 percentage points–49.8721.746.49
Inventory growth less cost-of-goods growthOur threshold 0 percentage points–16.9559.7614.86
Other current assets growth less revenue growthOur threshold 5 per cent of revenue–0.180.100.70
Assets under construction, years of additionsOur threshold 2 years of additions–––0.06
Effective tax ratePublished threshold 17.16 per cent25.9024.7826.5723.47
Tax charged less tax paid, % of profitOur threshold 10 percentage points3.7210.6312.983.75
A threshold marked as ours has no published figure; it is the line we read the check against.

Credit ratings

An agency's view of the chance the company repays a borrowing on time, from AAA, the highest, down to D, in default.

DateAgencyBorrowing ratedRatingOutlookAmount, ₹ Cr
23 Sep 2026CRISIL Ratings LimitedBank FacilitiesLong-term scaleCrisil BBBNo Rating ChangeStable23
23 Sep 2026CRISIL Ratings LimitedBank FacilitiesLong-term scaleCrisil BBBNo Rating ChangeStable6.63
23 Sep 2026CRISIL Ratings LimitedBank FacilitiesLong-term scaleCrisil BBBNo Rating ChangeStable17
23 Sep 2026CRISIL Ratings LimitedBank FacilitiesLong-term scaleCrisil BBBNo Rating ChangeStable110.87
23 Sep 2026CRISIL Ratings LimitedBank FacilitiesLong-term scaleCrisil BBBNo Rating ChangeStable18
23 Sep 2026CRISIL Ratings LimitedBank FacilitiesShort-term scaleCrisil A3+No Rating Change48
23 Sep 2026CRISIL Ratings LimitedBank FacilitiesLong-term scaleCrisil BBBNo Rating ChangeStable136.50
9 Sep 2025Infomerics Valuation and Ratings Private LimitedShort Term Bank Facilities - ProposedShort-term scaleIVR A3Review, Re-affirm52
9 Sep 2025Infomerics Valuation and Ratings Private LimitedShort Term Bank FacilitiesShort-term scaleIVR A3Review, Re-affirm48
9 Sep 2025Infomerics Valuation and Ratings Private LimitedLong term Bank Facilities - ProposedLong-term scaleIVR BBB-Review, Re-affirmPositive120.50
9 Sep 2025Infomerics Valuation and Ratings Private LimitedLong Term FacilitiesLong-term scaleIVR BBB-Review, Re-affirmPositive136.80
The latest rating on each borrowing. The agency's name opens its reasoning for the rating.